66 related articles for article (PubMed ID: 35740571)
41. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer.
Paris PL; Kobayashi Y; Zhao Q; Zeng W; Sridharan S; Fan T; Adler HL; Yera ER; Zarrabi MH; Zucker S; Simko J; Chen WT; Rosenberg J
Cancer Lett; 2009 May; 277(2):164-73. PubMed ID: 19162393
[TBL] [Abstract][Full Text] [Related]
42. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer.
Fan T; Zhao Q; Chen JJ; Chen WT; Pearl ML
Gynecol Oncol; 2009 Jan; 112(1):185-91. PubMed ID: 18954898
[TBL] [Abstract][Full Text] [Related]
43. Gene expression in fixed tissues and outcome in hepatocellular carcinoma.
Hoshida Y; Villanueva A; Kobayashi M; Peix J; Chiang DY; Camargo A; Gupta S; Moore J; Wrobel MJ; Lerner J; Reich M; Chan JA; Glickman JN; Ikeda K; Hashimoto M; Watanabe G; Daidone MG; Roayaie S; Schwartz M; Thung S; Salvesen HB; Gabriel S; Mazzaferro V; Bruix J; Friedman SL; Kumada H; Llovet JM; Golub TR
N Engl J Med; 2008 Nov; 359(19):1995-2004. PubMed ID: 18923165
[TBL] [Abstract][Full Text] [Related]
44. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases.
Xu L; Shen SS; Hoshida Y; Subramanian A; Ross K; Brunet JP; Wagner SN; Ramaswamy S; Mesirov JP; Hynes RO
Mol Cancer Res; 2008 May; 6(5):760-9. PubMed ID: 18505921
[TBL] [Abstract][Full Text] [Related]
45. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.
Deeley RG; Westlake C; Cole SP
Physiol Rev; 2006 Jul; 86(3):849-99. PubMed ID: 16816140
[TBL] [Abstract][Full Text] [Related]
46. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research.
Gottesman MM; Ling V
FEBS Lett; 2006 Feb; 580(4):998-1009. PubMed ID: 16405967
[TBL] [Abstract][Full Text] [Related]
47. Repopulation of cancer cells during therapy: an important cause of treatment failure.
Kim JJ; Tannock IF
Nat Rev Cancer; 2005 Jul; 5(7):516-25. PubMed ID: 15965493
[TBL] [Abstract][Full Text] [Related]
48. Identifying differentially expressed genes using false discovery rate controlling procedures.
Reiner A; Yekutieli D; Benjamini Y
Bioinformatics; 2003 Feb; 19(3):368-75. PubMed ID: 12584122
[TBL] [Abstract][Full Text] [Related]
49. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
Klement G; Baruchel S; Rak J; Man S; Clark K; Hicklin DJ; Bohlen P; Kerbel RS
J Clin Invest; 2000 Apr; 105(8):R15-24. PubMed ID: 10772661
[TBL] [Abstract][Full Text] [Related]
50. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Browder T; Butterfield CE; Kräling BM; Shi B; Marshall B; O'Reilly MS; Folkman J
Cancer Res; 2000 Apr; 60(7):1878-86. PubMed ID: 10766175
[TBL] [Abstract][Full Text] [Related]
51. ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer.
Isacoff WH; Cooper B; Bartlett A; McCarthy B; Yu KH
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740571
[TBL] [Abstract][Full Text] [Related]
52. Rationale for the use of metronomic chemotherapy in gastrointestinal cancer.
Filippi R; Lombardi P; Depetris I; Fenocchio E; Quarà V; Chilà G; Aglietta M; Leone F
Expert Opin Pharmacother; 2018 Sep; 19(13):1451-1463. PubMed ID: 30161003
[TBL] [Abstract][Full Text] [Related]
53. Tackling pancreatic cancer with metronomic chemotherapy.
Romiti A; Falcone R; Roberto M; Marchetti P
Cancer Lett; 2017 May; 394():88-95. PubMed ID: 28232048
[TBL] [Abstract][Full Text] [Related]
54. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
55. Metronomic Chemotherapy for Metastatic Breast Cancer.
Krajnak S; Battista MJ; Hasenburg A; Schmidt M
Oncol Res Treat; 2022; 45(1-2):12-17. PubMed ID: 34794154
[TBL] [Abstract][Full Text] [Related]
56. Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives.
Panthi VK; Dua K; Singh SK; Gupta G; Hansbro PM; Paudel KR
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111677
[TBL] [Abstract][Full Text] [Related]
57. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
58. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
59. Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress.
Xu B; Sun T; Wang S; Lin Y
Expert Rev Anticancer Ther; 2021 Jan; 21(1):71-79. PubMed ID: 33054438
[TBL] [Abstract][Full Text] [Related]
60. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.
Cazzaniga ME; Camerini A; Addeo R; Nolè F; Munzone E; Collovà E; Del Conte A; Mencoboni M; Papaldo P; Pasini F; Saracchini S; Bocci G
Future Oncol; 2016 Feb; 12(3):373-87. PubMed ID: 26584409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
